Global Manufacturing Capacity Delpharm operates 18 industrial sites across France, Italy, Canada, the Netherlands, and Poland, producing over one billion boxes annually. This extensive manufacturing footprint presents opportunities to offer advanced supply chain solutions, process optimization, and expansion collaborations to support their large-scale production demands.

Recent Capital Investments With recent investments of up to $140M in Canada and a $60M financing round, Delpharm is actively expanding and upgrading its facilities. These developments open avenues to provide high-tech equipment, modular cleanroom solutions, and facility modernization services to support their growth and technological advancements.

Strategic Partnerships & Expansion Delpharm has partnered with major industry players such as Pfizer and BioNTech for COVID vaccine fill & finish projects, indicating a strong focus on sterile and injectable manufacturing. This creates potential sales opportunities in sterile line equipment, biopharma development support, and specialized containment solutions.

Diverse Pharmaceutical Services Delpharm offers development and manufacturing across a wide range of dosage forms including tablets, capsules, injectables, and prefilled syringes. Businesses providing formulation development, serialization, or specialized packaging technologies can find tailored solutions for this multi-form capability.

Market Position & Growth As a growing leader with over 1.1 billion euros in revenue and a workforce exceeding 6,500 employees, Delpharm is positioned for continued expansion in Europe and North America. This presents opportunities for strategic collaborations, supply chain integrations, and technology partnerships aligned with their scale and market reach.